WO1994023740A1 - Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse - Google Patents

Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse Download PDF

Info

Publication number
WO1994023740A1
WO1994023740A1 PCT/US1994/001662 US9401662W WO9423740A1 WO 1994023740 A1 WO1994023740 A1 WO 1994023740A1 US 9401662 W US9401662 W US 9401662W WO 9423740 A1 WO9423740 A1 WO 9423740A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
tgf
bone
peg
hydrophilic polymer
Prior art date
Application number
PCT/US1994/001662
Other languages
English (en)
Inventor
Johanna Bentz
David M. Rosen
Cedo Bagi
Robert Brommage
Original Assignee
Celtrix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals, Inc. filed Critical Celtrix Pharmaceuticals, Inc.
Priority to AU65863/94A priority Critical patent/AU6586394A/en
Publication of WO1994023740A1 publication Critical patent/WO1994023740A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

l'invention se rapporte à un procédé de stimulation de la formation osseuse chez un animal qui consiste à administrer à l'animal une dose efficace d'un conjugué d'un facteur de croissance et d'un polymère hydrophile. De même une composition permettant de traiter la maladie ostéopénique des os comprend un conjugué d'un facteur de croissance et d'un polymère hydrophile. Les conjugués préférés comprennent, par exemple, un TGF-β comme facteur de croissance, et un polyéthylène glycol comme polymère hydrophile. Les facteurs de croissance conjugués aux polymères hydrophiles, selon l'invention, peuvent stimuler la formation osseuse à des niveaux de dosage inférieurs auxquels le facteur de croissance, non modifié, est inefficace; et les facteurs de croissance conjugués aux polymères hydrophiles, selon l'invention, favorisent une augmentation nette de la formation osseuse à des niveaux de dosage supérieurs auxquels le facteur de croissance, non modifié, provoque une réduction nette de la masse osseuse, dûe à la stimulation de la résorption osseuse et la formation osseuse par le facteur de croissance. Un inhibiteur de résorption osseuse est éventuellement ajouté afin de diminuer la résorption osseuse et par conséquent de stimuler la formation osseuse.
PCT/US1994/001662 1993-04-22 1994-02-16 Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse WO1994023740A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65863/94A AU6586394A (en) 1993-04-22 1994-02-16 Conjugates of growth factor and bone resorption inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5150893A 1993-04-22 1993-04-22
US08/051,508 1993-04-22
US8473293A 1993-06-28 1993-06-28
US08/084,732 1993-06-28

Publications (1)

Publication Number Publication Date
WO1994023740A1 true WO1994023740A1 (fr) 1994-10-27

Family

ID=26729493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/001662 WO1994023740A1 (fr) 1993-04-22 1994-02-16 Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse

Country Status (2)

Country Link
AU (1) AU6586394A (fr)
WO (1) WO1994023740A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028475A1 (fr) * 1995-03-10 1996-09-19 Nakamura, Toshikazu Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
WO1996039430A1 (fr) * 1995-06-06 1996-12-12 Hall Frederick L Proteines de fusion du tgf-beta et leur utilisation dans la cicatrisation de lesions
WO1998008517A2 (fr) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol
US6649168B2 (en) 1999-03-17 2003-11-18 Novartis Ag Pharmaceutical compositions comprising TGF-beta
US7635592B2 (en) 2000-08-21 2009-12-22 Rice University Tissue engineering scaffolds promoting matrix protein production
EP2196538A1 (fr) * 2000-02-10 2010-06-16 Mountain View Pharmaceuticals, Inc. Conjugués préparés avec des protéines sans agrégats
US7927589B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11982670B2 (en) 2023-02-01 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190695B1 (en) 1919-04-09 2001-02-20 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance
WO1996028475A1 (fr) * 1995-03-10 1996-09-19 Nakamura, Toshikazu Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
WO1996039430A1 (fr) * 1995-06-06 1996-12-12 Hall Frederick L Proteines de fusion du tgf-beta et leur utilisation dans la cicatrisation de lesions
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1998008517A2 (fr) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol
WO1998008517A3 (fr) * 1996-08-26 1998-05-07 Takeda Chemical Industries Ltd Composition pharmaceutique contenant une substance favorisant l'osteogenese et un polyethylene glycol
US8618267B2 (en) 1998-08-06 2013-12-31 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US7927589B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8067553B2 (en) 1998-08-06 2011-11-29 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8921064B2 (en) 1998-08-06 2014-12-30 Mountain View Pharmaceuticals, Inc. Method for purifying urate oxidase tetramers and octamers
US9885024B2 (en) 1998-08-06 2018-02-06 Duke University PEG-urate oxidase conjugates and use thereof
US6649168B2 (en) 1999-03-17 2003-11-18 Novartis Ag Pharmaceutical compositions comprising TGF-beta
EP2196538A1 (fr) * 2000-02-10 2010-06-16 Mountain View Pharmaceuticals, Inc. Conjugués préparés avec des protéines sans agrégats
US7635592B2 (en) 2000-08-21 2009-12-22 Rice University Tissue engineering scaffolds promoting matrix protein production
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10731139B2 (en) 2005-04-11 2020-08-04 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11345899B2 (en) 2005-04-11 2022-05-31 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US11781119B2 (en) 2005-04-11 2023-10-10 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10823727B2 (en) 2009-06-25 2020-11-03 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11982670B2 (en) 2023-02-01 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

Also Published As

Publication number Publication date
AU6586394A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
EP0512844B1 (fr) Délivrance ciblée de facteurs de croissance ostéogoniques
EP0977583B1 (fr) Compositions comprenant des conjugues de proteine ob humaine, active, stable avec une chaine fc d'immunoglobulins et leurs procedes
EP1037587B1 (fr) Preparation specifique a un site de conjugues de polyethylene glycol-grf
US8372422B2 (en) Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
US5118667A (en) Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5045312A (en) Physiologically active compositions of growth hormone and serum albumin or Ig G
AU727675B2 (en) Synthetic phosphopeptides for treating bone diseases
EP0828758B1 (fr) Analogues de pro-grf de corps gras chimere presentant une activite biologique accrue
EP1337274A2 (fr) Polyethyleneglycol ciblant l'hydroxyapatite et polymeres apparentes
KR20010018158A (ko) 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
JP7197468B2 (ja) 制御放出ｐｔｈ化合物の投薬レジメン
JP2007525499A (ja) 骨形成蛋白−２の正のモジュレーター
WO1994023740A1 (fr) Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse
EP4355763A1 (fr) Mimétiques d'hepcidine pour le traitement de l'hémochromatose héréditaire
US20020019352A1 (en) Stable, active, human ob protein compositions and methods
SK11312001A3 (sk) Soli farmaceuticky účinných peptidov s kontinuálnym uvoľňovaním a spôsob ich výroby
AU2005335186A1 (en) Human growth hormone conjugated with biocompatible polymer
US20230390363A1 (en) Compounds, Compositions and Methods of Use to Treat Spinal Fusions
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
MXPA97009098A (en) Chemical analogues of body grease-pro with biological power increment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA